Copyright © 2021. Inderes Oyj. All rights reserved.

The following resolutions were passed at the Annual General Meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 11 May 2022 in Lund.

Adoption of profit and loss account and balance sheet and discharge from liability
The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet for the financial year 2021. Furthermore, the members of the Board of Directors and the Managing Director were discharged from liability for the financial year 2021.
 
Allocation of profit
The AGM resolved, in accordance with the Board of Directors’ proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.
 
Board of Directors and auditor
The AGM resolved, in accordance with the Nomination committee’s proposal, on re-election of Mikael Worning, Christer Fåhraeus, Åsa Hedin and Stefan Wolf and new election of Ann-Charlotte Jarleryd as Board members. Mikael Worning was also re-elected as the Chairman of the Board of Directors. The AGM resolved on new election of the audit firm KPMG AB as auditor.
 
Furthermore, the AGM resolved on remuneration to the Board of Directors, remuneration to the auditor and additional remuneration for work in the Board’s committees in accordance with the Nomination committee’s proposal.
 
Nomination committee for the next Annual General Meeting
The AGM resolved, in accordance with the Nomination committee’s proposal, that the principles for appointing the Nomination committee which were adopted at the AGM in 2020 shall apply also for the AGM to be held in 2023.
 
Remuneration report
The AGM approved the Board of Directors’ remuneration report for the financial year 2021.

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.